Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study

John G F Cleland, P. Armstrong, J. D. Horowitz, B. Massie, M. Packer, P. A. Poole-Wilson, L. Rydén

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: The beneficial effect of ACE inhibitors on mortality has been established in a series of trials. However, in clinical practice, ACE inhibitors are commonly administered in doses much lower than those shown to be effective in the landmark trials. Aims: This report describes the baseline characteristics of the patients recruited into the ATLAS study by age and gender sub-groups. Methods: The ATLAS study compared the effects of 'low' dose (2.5-5.0 mg/day) to 'high' dose (32.5-35.0 mg/day) lisinopril in a double-blind study of 3164 patients with moderate to severe heart failure and left ventricular ejection fraction < 30% during a mean follow-up period of 46 months. The primary end-point was all cause mortality and the principal secondary end-point a composite of all-cause hospitalisation or all-cause mortality. Results: Among patients with heart failure selected for the presence of left ventricular systolic function there were few differences among age groups or between genders. Older patients were not so heavy, were more likely to have ischaemic heart disease, hypertension and atrial fibrillation contributing to their heart failure and had a higher blood urea. Women were not so heavy as men. Age and gender had no major influence on mean ejection fraction or baseline treatment in the ATLAS study. Conclusions: Weight and renal function may alter the plasma concentration of any given dose of an ACE inhibitor. Potential interactions between dose of lisinopril, weight and renal function will be explored after the study is completed. (C) 1999 European Society of Cardiology.

Original languageEnglish (US)
Pages (from-to)73-79
Number of pages7
JournalEuropean Journal of Heart Failure
Volume1
Issue number1
DOIs
StatePublished - Mar 2000

Fingerprint

Lisinopril
Angiotensin-Converting Enzyme Inhibitors
Survival
Heart Failure
Mortality
Kidney
Weights and Measures
Therapeutics
Left Ventricular Function
Double-Blind Method
Stroke Volume
Atrial Fibrillation
Myocardial Ischemia
Urea
Hospitalization
Age Groups
Hypertension

Keywords

  • ACE inhibitors
  • Dose
  • Lisinopril
  • Patients with heart failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cleland, J. G. F., Armstrong, P., Horowitz, J. D., Massie, B., Packer, M., Poole-Wilson, P. A., & Rydén, L. (2000). Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study. European Journal of Heart Failure, 1(1), 73-79. https://doi.org/10.1016/S1388-9842(98)00002-6

Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study. / Cleland, John G F; Armstrong, P.; Horowitz, J. D.; Massie, B.; Packer, M.; Poole-Wilson, P. A.; Rydén, L.

In: European Journal of Heart Failure, Vol. 1, No. 1, 03.2000, p. 73-79.

Research output: Contribution to journalArticle

Cleland, John G F ; Armstrong, P. ; Horowitz, J. D. ; Massie, B. ; Packer, M. ; Poole-Wilson, P. A. ; Rydén, L. / Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study. In: European Journal of Heart Failure. 2000 ; Vol. 1, No. 1. pp. 73-79.
@article{4f303e932a294e70a98fe6023ca7103c,
title = "Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study",
abstract = "Background: The beneficial effect of ACE inhibitors on mortality has been established in a series of trials. However, in clinical practice, ACE inhibitors are commonly administered in doses much lower than those shown to be effective in the landmark trials. Aims: This report describes the baseline characteristics of the patients recruited into the ATLAS study by age and gender sub-groups. Methods: The ATLAS study compared the effects of 'low' dose (2.5-5.0 mg/day) to 'high' dose (32.5-35.0 mg/day) lisinopril in a double-blind study of 3164 patients with moderate to severe heart failure and left ventricular ejection fraction < 30{\%} during a mean follow-up period of 46 months. The primary end-point was all cause mortality and the principal secondary end-point a composite of all-cause hospitalisation or all-cause mortality. Results: Among patients with heart failure selected for the presence of left ventricular systolic function there were few differences among age groups or between genders. Older patients were not so heavy, were more likely to have ischaemic heart disease, hypertension and atrial fibrillation contributing to their heart failure and had a higher blood urea. Women were not so heavy as men. Age and gender had no major influence on mean ejection fraction or baseline treatment in the ATLAS study. Conclusions: Weight and renal function may alter the plasma concentration of any given dose of an ACE inhibitor. Potential interactions between dose of lisinopril, weight and renal function will be explored after the study is completed. (C) 1999 European Society of Cardiology.",
keywords = "ACE inhibitors, Dose, Lisinopril, Patients with heart failure",
author = "Cleland, {John G F} and P. Armstrong and Horowitz, {J. D.} and B. Massie and M. Packer and Poole-Wilson, {P. A.} and L. Ryd{\'e}n",
year = "2000",
month = "3",
doi = "10.1016/S1388-9842(98)00002-6",
language = "English (US)",
volume = "1",
pages = "73--79",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study

AU - Cleland, John G F

AU - Armstrong, P.

AU - Horowitz, J. D.

AU - Massie, B.

AU - Packer, M.

AU - Poole-Wilson, P. A.

AU - Rydén, L.

PY - 2000/3

Y1 - 2000/3

N2 - Background: The beneficial effect of ACE inhibitors on mortality has been established in a series of trials. However, in clinical practice, ACE inhibitors are commonly administered in doses much lower than those shown to be effective in the landmark trials. Aims: This report describes the baseline characteristics of the patients recruited into the ATLAS study by age and gender sub-groups. Methods: The ATLAS study compared the effects of 'low' dose (2.5-5.0 mg/day) to 'high' dose (32.5-35.0 mg/day) lisinopril in a double-blind study of 3164 patients with moderate to severe heart failure and left ventricular ejection fraction < 30% during a mean follow-up period of 46 months. The primary end-point was all cause mortality and the principal secondary end-point a composite of all-cause hospitalisation or all-cause mortality. Results: Among patients with heart failure selected for the presence of left ventricular systolic function there were few differences among age groups or between genders. Older patients were not so heavy, were more likely to have ischaemic heart disease, hypertension and atrial fibrillation contributing to their heart failure and had a higher blood urea. Women were not so heavy as men. Age and gender had no major influence on mean ejection fraction or baseline treatment in the ATLAS study. Conclusions: Weight and renal function may alter the plasma concentration of any given dose of an ACE inhibitor. Potential interactions between dose of lisinopril, weight and renal function will be explored after the study is completed. (C) 1999 European Society of Cardiology.

AB - Background: The beneficial effect of ACE inhibitors on mortality has been established in a series of trials. However, in clinical practice, ACE inhibitors are commonly administered in doses much lower than those shown to be effective in the landmark trials. Aims: This report describes the baseline characteristics of the patients recruited into the ATLAS study by age and gender sub-groups. Methods: The ATLAS study compared the effects of 'low' dose (2.5-5.0 mg/day) to 'high' dose (32.5-35.0 mg/day) lisinopril in a double-blind study of 3164 patients with moderate to severe heart failure and left ventricular ejection fraction < 30% during a mean follow-up period of 46 months. The primary end-point was all cause mortality and the principal secondary end-point a composite of all-cause hospitalisation or all-cause mortality. Results: Among patients with heart failure selected for the presence of left ventricular systolic function there were few differences among age groups or between genders. Older patients were not so heavy, were more likely to have ischaemic heart disease, hypertension and atrial fibrillation contributing to their heart failure and had a higher blood urea. Women were not so heavy as men. Age and gender had no major influence on mean ejection fraction or baseline treatment in the ATLAS study. Conclusions: Weight and renal function may alter the plasma concentration of any given dose of an ACE inhibitor. Potential interactions between dose of lisinopril, weight and renal function will be explored after the study is completed. (C) 1999 European Society of Cardiology.

KW - ACE inhibitors

KW - Dose

KW - Lisinopril

KW - Patients with heart failure

UR - http://www.scopus.com/inward/record.url?scp=0033086882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033086882&partnerID=8YFLogxK

U2 - 10.1016/S1388-9842(98)00002-6

DO - 10.1016/S1388-9842(98)00002-6

M3 - Article

C2 - 10937983

AN - SCOPUS:0033086882

VL - 1

SP - 73

EP - 79

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 1

ER -